BELLUS Health to Participate in the 2021 RBC Capital Markets Global Healthcare Conference
May 12 2021 - 7:00AM
Business Wire
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the
“Company”), a clinical-stage biopharmaceutical company developing
novel therapeutics for the treatment of refractory chronic cough
("RCC") and other hypersensitization-related disorders, today
announced that Roberto Bellini, BELLUS Health's President and Chief
Executive Officer, will be participating in a fireside chat at the
2021 RBC Capital Markets Global Healthcare Conference.
Presentation Details:
Event: 2021 RBC Capital Markets Global Healthcare
Conference Date/Time: Wednesday, May 19, 2021 at 9:10 a.m.
ET
A live webcast of fireside chat may be accessed on the Events
& Presentations page under the Investors & Media section of
BELLUS Health's website at www.bellushealth.com. Following the
event, an archived webcast will be available on the Company’s
website.
About BELLUS Health (www.bellushealth.com)
BELLUS Health is a clinical-stage biopharmaceutical company
developing novel therapeutics for the treatment of RCC and other
hypersensitization-related disorders. The Company's product
candidate, BLU-5937, is being developed for the treatment of
refractory chronic cough (“RCC”) and chronic pruritus associated
with atopic dermatitis (“AD”).
RCC is a cough lasting more than 8 weeks despite appropriate
treatment for underlying condition(s). It is estimated that there
are approximately 9 million patients in the United States suffering
from RCC. RCC is associated with significant adverse physical,
social, and psychosocial effects on health and quality of life.
Currently, there is no specific therapy approved for RCC and
current treatment options are limited.
Chronic pruritus associated with AD is an irritating sensation
that leads to scratching and persists for longer than 6 weeks in AD
patients. It is estimated that up to 10% of adults in the United
States suffer from AD – almost all report symptoms of pruritus with
over 50% of patients attributing chronic pruritus as their most
burdensome symptom. Despite currently available treatments
targeting AD, there continues to be a lack of options targeting the
burden of pruritus in patients with AD.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210512005170/en/
Danny Matthews Director, Investor Relations and Communications
danny@bellushealth.com
Media: Julia Deutsch Solebury Trout
jdeutsch@soleburytrout.com
BELLUS Health (TSX:BLU)
Historical Stock Chart
From Aug 2024 to Sep 2024
BELLUS Health (TSX:BLU)
Historical Stock Chart
From Sep 2023 to Sep 2024